Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMD-G1 for Diabetic Foot Ulcers
NCT02361931Phase 2Completed
- Sponsor
- Remedor Biomed
- Start
- Mar 2016
- Primary completion
- Jun 2018
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of erythropoietin chitosan gel in diabetic foot ulcer (DFU) (2 arms), sponsored by Remedor Biomed. Primary endpoints: Number of participants without adverse events following RMD-G1 treatment at 24 weeks and Number of participants with the reduction of wound area by 75% or more at 12 weeks. Started Mar 2016; status: completed.
02
Drugs
erythropoietin chitosan gel
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02361931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02361931.